Business Context and Reporting Period
This Form 8-K filing by Oramed Pharmaceuticals Inc. reports a corporate governance event dated June 6, 2024. The Company is a Delaware corporation with principal executive offices in New York, New York, and its common stock trades on the Nasdaq Capital Market and Tel Aviv Stock Exchange under the symbol ORMP.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported figures for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material change reported is the appointment of Mr. Avraham Gabay to the roles of Chief Financial Officer, Treasurer, and Secretary, effective June 18, 2024. Mr. Gabay previously served as the Company's CFO from 2019 to 2021 and as CFO of Oravax Inc. (a 63% owned subsidiary) from 2021 to 2023.
Management Commentary and Compensation
- Compensation: Mr. Gabay's gross monthly salary is set at NIS 68,000, and he will be provided with a company car.
- Equity and Bonuses: He is eligible for bonuses and equity grants, with amounts to be determined at the discretion of the Board of Directors and the Compensation Committee.
- Agreements: The appointment is governed by an employment agreement with Oramed Ltd. (the Company's wholly-owned Israeli subsidiary) and a standard indemnification agreement.
- Related Transactions: The filing states Mr. Gabay is not a party to any transactions disclosable under Item 404 of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Mr. Gabay's appointment (June 18, 2024) against internal corporate records.
- Confirm the specific terms of the employment agreement with Oramed Ltd., particularly regarding the NIS 68,000 monthly salary and company car provision.
- Monitor future filings for the specific amounts of bonuses and equity grants to be determined by the Compensation Committee.
- Review Mr. Gabay's prior tenure as CFO of Oravax Inc. and the Company to assess continuity in financial strategy.